Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis
Purpose This retrospective analysis aimed to assess the therapeutic efficacy and adverse event profile of tislelizumab combined with lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC), predominantly of hepatitis B virus (HBV) etiology. While this combination has shown promise i...
Zapisane w:
| Główni autorzy: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
PeerJ Inc.
2026-01-01
|
| Seria: | PeerJ |
| Hasła przedmiotowe: | |
| Dostęp online: | https://peerj.com/articles/20591.pdf |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|